首页> 外文OA文献 >Novel Anti-FOLR1 Antibody–Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells

【2h】

Novel Anti-FOLR1 Antibody–Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells

机译：新型抗-Folr1抗体 - 药物缀合物Morab-202在乳腺癌和非小细胞肺癌细胞中

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Yuki Matsunaga; Toshimitsu Yamaoka; Motoi Ohba; Sakiko Miura; Hiroko Masuda; Takafumi Sangai; Masafumi Takimoto; Seigo Nakamura; Junji Tsurutani;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer [J] . Journal of international management . 2020,第2期

机译：非小细胞肺癌和抗铂卵巢癌患者抗NAPI2B抗体 - 药物共轭寿命的抗NAPI2B抗体 - 药物缀合物Lifastuzumab Vedotin DNIB0600A
2. Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer [J] . Gerber David E., Infante Jeffrey R., Gordon Michael S., Clinical cancer research: an official journal of the American Association for Cancer Research . 2020,第2期

机译：抗NaPi2B抗体 - 药物缀合物Lifastuzumab Vedotin DNIB0600A的IA类研究，非小细胞肺癌和抗铂卵巢癌患者
3. Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers [J] . Lin Kedan, Rubinfeld Bonnee, Zhang Crystal, Clinical cancer research: an official journal of the American Association for Cancer Research . 2015,第22期

机译：抗NaPi2b（SLC34A2）抗体-药物偶联物的临床前开发，可用于治疗非小细胞肺癌和卵巢癌
4. Development of an Antibody-Drug Conjugate Targeting the MUC1-C Oncoprotein on Human Cancer Cells [C] . Govindaswamy Panchamoorthy, Gaining Jin, Deepak Raina, Protein Engineering Summit. . 2018

机译：靶向人癌细胞上的MUC1-C癌蛋白的抗体 - 药物缀合物的研制
5. Design and Evaluation of Peptidomimetics and Peptidomimetics Drug Conjugates Targeting HER2 Overexpressing Cells in Breast and Lung Cancers [D] . Pallerla, Sandeep. 2017

机译：拟肽和拟肽药物结合物靶向乳腺癌和肺癌中HER2过表达细胞的设计和评估
6. Novel Anti-FOLR1 Antibody–Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells [O] . Yuki Matsunaga, Toshimitsu Yamaoka, Motoi Ohba, 2021

机译：新型抗-Folr1抗体 - 药物缀合物Morab-202在乳腺癌和非小细胞肺癌细胞中
7. Circulating tumour DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met [O] . R.S. Heist, M. Motwani, L. Naumovski, 2019

机译：用Telisotuzumab Vedotin（Teliso-V）处理的非小细胞肺癌（NSCLC）循环肿瘤DNA（CTDNA）分析（PTS），靶向C-Met的抗体 - 药物缀合物

Novel Anti-FOLR1 Antibody–Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells

著录项

引文网络

相似文献

相关主题

期刊订阅